Neuland Laboratories Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xug45jn3303d2jaolb8layja.pdf

Key Takeaways


Commercial CMS: The Growth Engine and Its Concentration

Saharsh Davuluri: "Yes, there will be certain lumpiness in how they perform, like maybe we will not have orders every quarter, etc., but there is nothing which is like a one-off performance from the commercial CMS pipeline that we have. But the reality is that there are only a handful of these molecules. And to be frank, we're glad that it's a handful and it's not just one."

Development Pipeline and Future Commercialization


Peptides and the Gland Pharma Partnership

Saharsh Davuluri: "At that point, the investment was based on our conviction regarding long-term attractiveness of the segment. Today, we are beginning to see external validation of that thesis."
Saharsh Davuluri: "For us to move into making sterile product would attract a sort of a lot of risks associated with managing sterile facilities. And that's something that as management of Neuland, we thought we should try to avoid... it's an asset-light arrangement for us. So, without necessarily getting into the rig role of creating an asset and managing it, etcetera, we are able to rely on this partnership."

Margins, Returns, and the Investment Cycle

Saharsh Davuluri: "We are operating at that convergence of GMP and complex chemistry. That's where we operate... And if our modus operandi is complex chemistry, then our future, it only has to be more and more complex. It cannot be more and more simpler, which means that we will be seeking presence in newer modalities, more complex modalities."

Working Capital and Balance Sheet


GDS and the Broader Portfolio


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth aspirationGrow at about 20%FY27 and FY28
Peptide plant commissioningPlant to be commissioned next month, then ready for manufacturing qualificationSeptember 2026
Commercial molecule diversificationOne more commercialization this year, 1-2 next yearFY27 and FY28
Development revenue trajectoryDevelopment revenue to increase, with more molecules contributing to commercial revenueFY28 onwards
Long-term EBITDA margin25% plusLong-term target
Stock split/bonus considerationManagement to take shareholder suggestion to the Board for discussionNo timeline given

Key Metrics

MetricQ1 FY27
Total income₹650.1 cr, +16.3% YoY
EBITDA₹231.1 cr, EBITDA margin 35.5%
Gross margin61.2%, up from 55.3% in Q1 FY26
Profit after tax₹147.4 cr, vs ₹13.7 cr in Q1 FY26
Earnings per share₹114.9 per share
Working capital days84 days, improved from 137 days at end of FY26
Capex (cash outflow)₹121.6 cr, primarily for new R&D and peptide facilities
Capex approved during quarter₹203 cr, of which ₹196 cr for strategic growth initiatives, largely Unit 1 capacity expansion
Total approved capex (last 13 quarters)₹1,460 cr, with ₹870 cr spent to date
Commercial CMS drivers~3 molecules driving majority of commercial CMS revenue
Development pipeline additions2 new projects in FY27 so far, fairly advanced in the clinic
Expected near-term commercializations1 more expected in FY27, 1 or maybe 2 in FY28
Long-term EBITDA margin target25% plus
FY27–FY28 growth aspiration~20%